Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Anika Therapeutics, Inc.
  6. Financials
    ANIK   US0352551081

ANIKA THERAPEUTICS, INC.

(ANIK)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
22.53 USD   -4.13%
06/10ANIKA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
06/10Anika to Participate in the Sidoti Small Cap Virtual Investor Conference
GL
06/10Anika to Participate in the Sidoti Small Cap Virtual Investor Conference
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 740643517328--
Enterprise Value (EV)1 740643423328328328
P/E ratio 27,4x-26,8x128x-29,8x92,6x62,6x
Yield ------
Capitalization / Revenue 6,46x4,93x3,50x2,12x1,93x1,79x
EV / Revenue 6,46x4,93x3,50x2,12x1,93x1,79x
EV / EBITDA 15,0x26,9x31,5x43,8x30,8x16,4x
Price to Book --1,80x---
Nbr of stocks (in thousands) 14 26914 21514 43714 544--
Reference price (USD) 51,945,335,822,522,522,5
Announcement Date 02/20/202003/04/202103/08/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 115130148154170183
EBITDA1 49,223,916,47,4810,720,0
Operating profit (EBIT)1 37,1-28,32,62-13,44,704,74
Operating Margin 32,4%-21,7%1,77%-8,65%2,76%2,60%
Pre-Tax Profit (EBT)1 36,1-28,62,43-13,35,034,98
Net income1 27,2-24,04,13-11,03,555,47
Net margin 23,7%-18,4%2,80%-7,10%2,09%3,00%
EPS2 1,89-1,690,28-0,760,240,36
Dividend per Share ------
Announcement Date 02/20/202003/04/202103/08/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 39,535,836,737,939,540,4
EBITDA1 5,75-0,202,610,791,522,57
Operating profit (EBIT)1 1,30-9,12-3,55-3,95-3,16-2,69
Operating Margin 3,29%-25,5%-9,69%-10,4%-7,99%-6,66%
Pre-Tax Profit (EBT)1 1,25-9,17-3,71-3,88-3,08-2,61
Net income1 0,56-5,79-2,93-3,28-2,59-2,16
Net margin 1,41%-16,2%-7,99%-8,67%-6,55%-5,35%
EPS2 0,04-0,40-0,20-0,23-0,18-0,15
Dividend per Share ------
Announcement Date 11/04/202103/08/202205/05/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt ------
Net Cash position --94,4---
Leverage (Debt / EBITDA) ---5,74x---
Free Cash Flow1 34,211,43,25-5,9814,98,62
ROE (Net Profit / Equities) 10,7%-8,55%1,48%-2,50%9,40%-
Shareholders' equity1 25528028043937,8-
ROA (Net Profit / Asset) 9,66%-6,89%1,16%-2,10%8,00%-
Assets1 28234835752244,4-
Book Value Per Share --19,9---
Cash Flow per Share ------
Capex1 2,831,635,148,8110,38,50
Capex / Sales 2,47%1,25%3,48%5,71%6,02%4,65%
Announcement Date 02/20/202003/04/202103/08/2022---
1 USD in Million
Previous periodNext period
Estimates
Key data
Capitalization (USD) 327 673 165
Net sales (USD) 147 794 000
Number of employees 297
Sales / Employee (USD) 497 623
Free-Float 98,1%
Free-Float capitalization (USD) 321 395 203
Avg. Exchange 20 sessions (USD) 3 372 673
Average Daily Capital Traded 1,03%
EPS & Dividend
Year-on-year evolution of the PER